These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30043330)

  • 41. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
    Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI
    Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Wagstaff AJ
    Drugs; 2009; 69(3):319-26. PubMed ID: 19275275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
    Keating GM
    Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
    Valtola J; Varmavuo V; Ropponen A; Nihtinen A; Partanen A; Vasala K; Lehtonen P; Penttilä K; Pyörälä M; Kuittinen T; Silvennoinen R; Nousiainen T; Pelkonen J; Mäntymaa P; Jantunen E
    Transfusion; 2015 Oct; 55(10):2358-68. PubMed ID: 26018461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.
    Shi PA; Miller LK; Isola LM
    Transfusion; 2014 May; 54(5):1263-8. PubMed ID: 24128272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plerixafor: what we still have to learn.
    Lanza F; Gardellini A; Laszlo D; Martino M
    Expert Opin Biol Ther; 2015 Feb; 15(2):143-7. PubMed ID: 25315706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etoposide + Granulocyte Colony-Stimulating Factor and Optional Plerixafor in Patients Who Failed Chemomobilization with or without Plerixafor.
    Zucenka A; Peceliunas V; Maciutaite E; Chaleckaite J; Jakimaviciute R; Griskevicius L
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1304-1311. PubMed ID: 30871977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
    Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation.
    Sanikommu SR; Reese ES; He J; Lee C; Ai J; Butler CM; Jacobs R; Hu B; Atrash S; Trivedi J; Bhutani M; Voorhees P; Usmani SZ; Ghosh N; Fasan O; Druhan LJ; Symanowski J; Copelan EA; Avalos BR
    J Clin Apher; 2021 Aug; 36(4):553-562. PubMed ID: 33710672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
    DiPersio JF; Stadtmauer EA; Nademanee A; Micallef IN; Stiff PJ; Kaufman JL; Maziarz RT; Hosing C; Früehauf S; Horwitz M; Cooper D; Bridger G; Calandra G;
    Blood; 2009 Jun; 113(23):5720-6. PubMed ID: 19363221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
    Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
    J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.